Tune Therapeutics has received clinical trial application approval from the New Zealand Medicines and Medical Devices Safety Authority to initiate a...
Researchers have developed a compact, all-in-one CRISPR-dCas9-based repressor platform delivered via AAV, effectively silencing gene expression...
In a recent study, researchers in Italy addressed the critical need for experimental validation of durable epigenetic silencing after transient...
By targeting a highly conserved master controller sequence, Tune Therapeutics' lead candidate TUNE-401 can epigenetically silence all forms of the...
Gene-editing systems, especially CRISPR-Cas9, have revolutionised genome editing, offering potential cures for genetic disorders, cancers, and other...
Webinar
Webinar | Wednesday November 22, 2023 | 3:00 pm–4:00 pm CET / 9:00 am–10:00 am EDT
Leading epigeneticist Gabriella Ficz has used CRISPR technology to investigate the interplay between DNA methylation and cancer. Her latest findings...
